FDA Grants Incyte’s Jakafi Breakthrough Therapy Designation

Incyte’s Jakafi has secured breakthrough therapy designation for treatment of patients with acute graft-versus-host disease, the Wilmington, Del.-based company announced last week.

Jakafi is indicated to treat people with polycythemia vera who aren’t responsive to hydroxyurea, as well as people with intermediate or high-risk myelofibrosis.

Currently, there are no approved treatments for patients with acute GVHD.